Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
Open Access
- 19 September 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal – Cardiovascular Imaging
- Vol. 15 (10), 1063-1093
- https://doi.org/10.1093/ehjci/jeu192
Abstract
### A. Definition, classification, and mechanisms of toxicity Cardiac dysfunction resulting from exposure to cancer therapeutics was first recognized in the 1960s, with the widespread introduction of anthracyclines into the oncological therapeutic armamentarium.1 Heart failure (HF) associated with anthracyclines was then recognized as an important side effect. As a result, physicians learned to limit their doses to avoid cardiac dysfunction.2 Several strategies have been used over the past decades to detect it. Two of them evolved over time to be very useful: endomyocardial biopsies and monitoring of left ventricular (LV) ejection fraction (LVEF) by cardiac imaging. Examination of endomyocardial biopsies proved to be the most sensitive and specific parameter for the identification of anthracycline-induced LV dysfunction and became the gold standard in the 1970s. However, the interest in endomyocardial biopsy has diminished over time because of the reduction in the cumulative dosages used to treat malignancies, the invasive nature of the procedure, and the remarkable progress made in non-invasive cardiac imaging. The non-invasive evaluation of LVEF has gained importance, and notwithstanding the limitations of the techniques used for its calculation, has emerged as the most widely used strategy for monitoring the changes in cardiac function, both during and after the administration of potentially cardiotoxic cancer treatment.3–5 The timing of LV dysfunction can vary among agents. In the case of anthracyclines, the damage occurs immediately after the exposure;6 for others, the time frame between drug administration and detectable cardiac dysfunction appears to be more variable. Nevertheless, the heart has significant cardiac reserve, and the expression of damage in the form of alterations in systolic or diastolic parameters may not be overt until a substantial amount of cardiac reserve has been exhausted. Thus, cardiac damage may not become apparent until years or even decades after receiving the cardiotoxic treatment. This is particularly applicable to …Keywords
This publication has 165 references indexed in Scilit:
- Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugsJournal of Nuclear Cardiology, 2012
- Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trialThe Lancet, 2012
- Role of Biomarkers in Chemotherapy-Induced CardiotoxicityProgress in Cardiovascular Diseases, 2010
- Anthracycline-Induced Cardiomyopathy: Clinical Relevance and Response to Pharmacologic TherapyJournal of the American College of Cardiology, 2010
- Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose ChemotherapyCirculation, 2004
- Enalapril to Prevent Cardiac Function Decline in Long-Term Survivors of Pediatric Cancer Exposed to AnthracyclinesJournal of Clinical Oncology, 2004
- Underlying Causes and Long-Term Survival in Patients with Initially Unexplained CardiomyopathyThe New England Journal of Medicine, 2000
- Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: Seven-year experience using serial radionuclide angiocardiographyAmerican Journal Of Medicine, 1987
- Clinical and morphologic cardiac findings after anthracycline chemotherapy: Analysis of 64 patients studied at necropsyThe American Journal of Cardiology, 1983
- Serial Assessment of Doxorubicin Cardiotoxicity with Quantitative Radionuclide AngiocardiographyThe New England Journal of Medicine, 1979